MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, TGTX has $1,025,024K in assets. $417,806K in debts. $74,081K in cash and cash equivalents.

Balance Sheets Overview

Current Ratio
382.48%
Quick Ratio
288.76%
Cash Ratio
47.24%
Debt to Asset Ratio
40.76%
Assets Breakdown
    • Deferred tax assets
    • Accounts receivable, net
    • Inventories
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Loan payable non-current
    • Others

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Balance Sheets
2025-09-30
2025-06-30
Cash and cash equivalents
74,081 129,126
Short-term investment securities
57,501 122,744
Accounts receivable, net
265,384 231,516
Inventories
146,953 155,202
Other current assets
55,846 25,374
Total current assets
599,765 663,962
Restricted cash
1,329 1,316
Long-term investment securities
48,757 28,590
Right of use assets
6,501 6,718
Deferred tax assets
366,627 -
Other noncurrent assets
2,045 2,027
Total assets
1,025,024 702,613
Accounts payable and accrued expenses
112,336 134,021
Other current liabilities
1,993 2,256
Lease liability current portion
1,068 1,091
Deferred revenue - current portion
26,399 23,911
Accrued compensation
15,014 10,610
Total current liabilities
156,810 171,889
Deferred revenue, non-current portion
8,348 1,667
Loan payable non-current
245,340 245,037
Lease liability non-current
7,308 7,588
Total liabilities
417,806 426,181
Common stock, 0.001 par value per share (190,000,000 and 175,000,000 shares authorized, 158,754,176 and 156,204,159 shares issued, 155,210,533 and 155,836,256 shares outstanding at september 30, 2025 and december 31, 2024, respectively)
159 159
Additional paid-in capital
1,812,345 1,794,212
Treasury stock, at cost, 761,098 and 367,903 shares at june 30, 2025 and december 31, 2024, respectively
-21,992
Treasury stock, at cost, 3,543,643 and 367,903 shares at september 30, 2025 and december 31, 2024, respectively
100,234 -
Accumulated deficit
-1,105,052 -1,495,947
Total stockholders equity
607,218 276,432
Total liabilities and stockholders equity
1,025,024 702,613
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Other current assets$55,846K Inventories$146,953K Accounts receivable, net$265,384K Short-term investmentsecurities$57,501K Cash and cashequivalents$74,081K Other noncurrentassets$2,045K Deferred tax assets$366,627K Right of use assets$6,501K Long-term investmentsecurities$48,757K Restricted cash$1,329K Total current assets$599,765K Total assets$1,025,024K Total liabilities andstockholders equity$1,025,024K Total stockholdersequity$607,218K Total liabilities$417,806K Accumulated deficit-$1,105,052K Treasury stock, at cost,3,543,643 and 367,903...$100,234K Additional paid-in capital$1,812,345K Lease liability non-current$7,308K Loan payable non-current$245,340K Deferred revenue,non-current portion$8,348K Total currentliabilities$156,810K Common stock, 0.001 parvalue per share...$159K Accrued compensation$15,014K Deferred revenue -current portion$26,399K Lease liability current portion$1,068K Other currentliabilities$1,993K Accounts payable andaccrued expenses$112,336K

TG Therapeutics BRIUMVI Approval Call Slide Deck 12

TG THERAPEUTICS, INC. (TGTX)

TG Therapeutics BRIUMVI Approval Call Slide Deck 12

TG THERAPEUTICS, INC. (TGTX)